Home › Companies › Enanta Pharmaceuticals, Inc. › 2025-2026
Compiled from SEC Form N-PX filings and Enanta Pharmaceuticals, Inc.’s Form 8-K, filed March 12, 2026 (Item 5.07 on EDGAR). Page generated October 18, 2026.
Meeting of March 11, 2026: 5 items on Enanta Pharmaceuticals, Inc.’s Form 8-K, filed March 12, 2026: 2 elected · 3 approved.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Explore Enanta Pharmaceuticals, Inc. in the interactive database Compare manager voting policies
These tallies are Enanta Pharmaceuticals, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed March 12, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Bruce L.A. Carter, Ph.D. | 20,289,217 | -- | -- | 4,634,123 | 1,929,393 | 81% | Elected | — |
| Elect Director: Jay R. Luly, Ph.D. | 24,728,854 | -- | -- | 194,486 | 1,929,393 | 99.2% | Elected | — |
| 2. To Approve an Amendment to Our 2019 Equity Incentive Plan | 19,528,223 | 5,390,888 | 4,229 | -- | 1,929,393 | 78% | Approved | — |
| 3. To Approve, on an Advisory Basis, the Compensation Paid to the Company's Named Executive Officers | 24,228,898 | 692,079 | 2,363 | -- | 1,929,393 | 97% | Approved | — |
| 4. To Ratify the Appointment of PricewaterhouseCoopers LLP as Enanta's Independent Registered Public Accounting Firm for the 2026 Fiscal Year | 26,825,173 | 26,904 | 656 | -- | 0 | 99.8% | Approved | — |
Source: Enanta Pharmaceuticals, Inc., Form 8-K, filed with the SEC on March 12, 2026 — read the filing on EDGAR.
Each item below shows how the 161 asset managers that disclosed a Enanta Pharmaceuticals, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 4 wordings of this item as funds reported it.
81% Majority: yes · of votes cast
Description as filed by funds: To elect two Class I directors to serve until the 2029 Annual Meeting of Stockholders or until their respective successors are elected and qualified: Bruce L.A. Carter, Ph.D.
Enanta Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Bruce L.A. Carter, Ph.D.”): 20,289,217 for, 4,634,123 withheld, per its Form 8-K filed March 12, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “The stockholders re-elected the following individuals as Class I directors of the Company:”
Support: 81% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 49 asset managers below reported 4,618,162 for, 1,249,027 withheld, 4,700 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 1,150,227 | 0 | 0 | 952,495 | Mixed |
| BlackRock | 1,930,161 | 0 | 0 | 0 | For |
| Fidelity | 563,274 | 0 | 0 | 0 | For |
| Charles Schwab | 270,405 | 0 | 0 | 0 | For |
| Invesco | 0 | 0 | 0 | 223,352 | Withhold |
| Dimensional | 88,219 | 0 | 0 | 0 | For |
| Goldman Sachs | 86,245 | 0 | 0 | 0 | For |
| TIAA | 84,434 | 0 | 0 | 0 | For |
| Equitable | 44,634 | 0 | 0 | 21,930 | Mixed |
| JPMorgan | 62,555 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 46,159 | 0 | 0 | 0 | For |
| TARGET PORTFOLIO TRUST | 33,700 | 0 | 0 | 0 | For |
| Thrivent | 27,269 | 0 | 0 | 0 | For |
| Brighthouse | 26,289 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 25,428 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 25,000 | 0 | 0 | 0 | For |
| Northern Trust | 0 | 0 | 0 | 22,122 | Withhold |
| Lincoln Financial | 20,378 | 0 | 0 | 0 | For |
| Nationwide | 17,210 | 0 | 0 | 0 | For |
| Franklin Templeton | 16,948 | 0 | 0 | 0 | For |
| Putnam | 14,847 | 0 | 0 | 0 | For |
| Global X | 0 | 0 | 0 | 12,668 | Withhold |
| Bridge Builder Trust | 12,096 | 0 | 0 | 0 | For |
| Pacific Life | 10,277 | 0 | 0 | 0 | For |
| SEI | 0 | 0 | 4,700 | 5,130 | Mixed |
Showing the 25 largest of 49 asset managers. See all 49 in the interactive database.
Combines 5 wordings of this item as funds reported it.
99.2% Majority: yes · of votes cast
Description as filed by funds: To elect two Class I directors to serve until the 2029 Annual Meeting of Stockholders or until their respective successors are elected and qualified: Jay R. Luly, Ph.D.
Enanta Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Jay R. Luly, Ph.D.”): 24,728,854 for, 194,486 withheld, per its Form 8-K filed March 12, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “The stockholders re-elected the following individuals as Class I directors of the Company:”
Support: 99.2% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 49 asset managers below reported 5,870,100 for, 1,789 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,102,722 | 0 | 0 | 0 | For |
| BlackRock | 1,930,161 | 0 | 0 | 0 | For |
| Fidelity | 563,274 | 0 | 0 | 0 | For |
| Charles Schwab | 270,405 | 0 | 0 | 0 | For |
| Invesco | 223,352 | 0 | 0 | 0 | For |
| Dimensional | 88,219 | 0 | 0 | 0 | For |
| Goldman Sachs | 86,245 | 0 | 0 | 0 | For |
| TIAA | 84,434 | 0 | 0 | 0 | For |
| Equitable | 66,564 | 0 | 0 | 0 | For |
| JPMorgan | 62,555 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 46,159 | 0 | 0 | 0 | For |
| TARGET PORTFOLIO TRUST | 33,700 | 0 | 0 | 0 | For |
| Thrivent | 27,269 | 0 | 0 | 0 | For |
| Brighthouse | 26,289 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 25,428 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 25,000 | 0 | 0 | 0 | For |
| Northern Trust | 22,122 | 0 | 0 | 0 | For |
| Lincoln Financial | 20,378 | 0 | 0 | 0 | For |
| Nationwide | 17,210 | 0 | 0 | 0 | For |
| Franklin Templeton | 16,948 | 0 | 0 | 0 | For |
| Putnam | 14,847 | 0 | 0 | 0 | For |
| Global X | 12,668 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 12,096 | 0 | 0 | 0 | For |
| Pacific Life | 10,277 | 0 | 0 | 0 | For |
| SEI | 9,830 | 0 | 0 | 0 | For |
Showing the 25 largest of 49 asset managers. See all 49 in the interactive database.
Combines 2 wordings of this item as funds reported it.
78% Approved · of votes cast
Description as filed by funds: TO APPROVE AN AMENDMENT TO OUR 2019 EQUITY INCENTIVE PLAN.
Enanta Pharmaceuticals, Inc.’s own tally for this item (“2. To Approve an Amendment to Our 2019 Equity Incentive Plan”): 19,528,223 for, 5,390,888 against — passed, per its Form 8-K filed March 12, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The stockholders approved the amendment to our 2019 Equity Incentive Plan to increase the number of shares of Common Stock reserved for issuance under the plan by 1,600,000 shares.”
Support: 78% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 49 asset managers below reported 4,164,148 for, 1,707,741 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 1,148,827 | 953,895 | 0 | 0 | Mixed |
| BlackRock | 1,930,161 | 0 | 0 | 0 | For |
| Fidelity | 554,055 | 9,219 | 0 | 0 | For |
| Charles Schwab | 270,405 | 0 | 0 | 0 | For |
| Invesco | 0 | 223,352 | 0 | 0 | Against |
| Dimensional | 0 | 88,219 | 0 | 0 | Against |
| Goldman Sachs | 0 | 86,245 | 0 | 0 | Against |
| TIAA | 0 | 84,434 | 0 | 0 | Against |
| Equitable | 44,634 | 21,930 | 0 | 0 | Mixed |
| JPMorgan | 62,555 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 46,159 | 0 | 0 | 0 | For |
| TARGET PORTFOLIO TRUST | 33,700 | 0 | 0 | 0 | For |
| Thrivent | 0 | 27,269 | 0 | 0 | Against |
| Brighthouse | 16,758 | 9,531 | 0 | 0 | Mixed |
| AIG/SunAmerica | 0 | 25,428 | 0 | 0 | Against |
| BRIDGEWAY FUNDS INC | 0 | 25,000 | 0 | 0 | Against |
| Northern Trust | 0 | 22,122 | 0 | 0 | Against |
| Lincoln Financial | 0 | 20,378 | 0 | 0 | Against |
| Nationwide | 8,455 | 8,755 | 0 | 0 | Mixed |
| Franklin Templeton | 0 | 16,948 | 0 | 0 | Against |
| Putnam | 0 | 14,847 | 0 | 0 | Against |
| Global X | 12,668 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 12,096 | 0 | 0 | 0 | For |
| Pacific Life | 10,277 | 0 | 0 | 0 | For |
| SEI | 8,815 | 1,015 | 0 | 0 | Mixed |
Showing the 25 largest of 49 asset managers. See all 49 in the interactive database.
Combines 4 wordings of this item as funds reported it.
97% Approved · of votes cast
Description as filed by funds: TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION PAID TO OUR NAMED EXECUTIVE OFFICERS, AS DISCLOSED IN THE PROXY STATEMENT.
Enanta Pharmaceuticals, Inc.’s own tally for this item (“3. To Approve, on an Advisory Basis, the Compensation Paid to the Company's Named Executive Officers”): 24,228,898 for, 692,079 against — passed, per its Form 8-K filed March 12, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The stockholders approved the advisory vote on executive compensation, referred to as a "say-on-pay" vote.”
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,102,722 | 0 | 0 | 0 | For |
| BlackRock | 1,930,161 | 0 | 0 | 0 | For |
| Fidelity | 563,274 | 0 | 0 | 0 | For |
| Charles Schwab | 270,405 | 0 | 0 | 0 | For |
| Invesco | 0 | 223,352 | 0 | 0 | Against |
| Dimensional | 88,219 | 0 | 0 | 0 | For |
| Goldman Sachs | 86,245 | 0 | 0 | 0 | For |
| TIAA | 84,434 | 0 | 0 | 0 | For |
| Equitable | 66,564 | 0 | 0 | 0 | For |
| JPMorgan | 62,555 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 46,159 | 0 | 0 | 0 | For |
| TARGET PORTFOLIO TRUST | 33,700 | 0 | 0 | 0 | For |
| Thrivent | 27,269 | 0 | 0 | 0 | For |
| Brighthouse | 26,289 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 25,428 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 0 | 25,000 | 0 | 0 | Against |
| Northern Trust | 22,122 | 0 | 0 | 0 | For |
| Lincoln Financial | 20,378 | 0 | 0 | 0 | For |
| Nationwide | 17,210 | 0 | 0 | 0 | For |
| Franklin Templeton | 16,948 | 0 | 0 | 0 | For |
| Putnam | 14,847 | 0 | 0 | 0 | For |
| Global X | 12,668 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 12,096 | 0 | 0 | 0 | For |
| Pacific Life | 10,277 | 0 | 0 | 0 | For |
| SEI | 9,830 | 0 | 0 | 0 | For |
Fund voting reports, all 49 managers: 5,623,537 for, 248,352 against. Showing the 25 largest; see all in the interactive database.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Janus Henderson | 6,866,954 | 0 | 0 | 0 | For |
| FARALLON CAPITAL MANAGEMENT, L.L.C. | 2,772,195 | 0 | 0 | 0 | For |
| Deep Track Capital, LP | 1,956,867 | 0 | 0 | 0 | For |
| BlackRock | 861,277 | 5,171 | 0 | 0 | For |
| ACADIAN ASSET MANAGEMENT LLC | 643,442 | 7,791 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 648,048 | 0 | 0 | 0 | For |
| State Street | 491,035 | 735 | 0 | 0 | For |
| Hillsdale Investment Management Inc. | 411,400 | 0 | 0 | 0 | For |
| Invesco | 0 | 276,023 | 0 | 0 | Against |
| Charles Schwab | 270,408 | 0 | 0 | 0 | For |
| Two Sigma | 208,152 | 0 | 0 | 0 | For |
| Renaissance | 190,927 | 0 | 0 | 0 | For |
| Vanguard | 185,179 | 0 | 0 | 0 | For |
| MARSHALL WACE, LLP | 181,262 | 0 | 0 | 0 | For |
| Northern Trust | 176,180 | 0 | 0 | 0 | For |
| PARAMETRIC PORTFOLIO ASSOCIATES LLC | 157,497 | 0 | 0 | 0 | For |
| Goldman Sachs | 101,316 | 0 | 0 | 0 | For |
| Stonepine Capital Management, LLC | 100,000 | 0 | 0 | 0 | For |
| DE Shaw | 98,906 | 0 | 0 | 0 | For |
| MELLON INVESTMENTS Corp | 90,467 | 0 | 0 | 0 | For |
| Nuveen | 86,056 | 0 | 0 | 0 | For |
| Point72 | 62,018 | 0 | 0 | 0 | For |
| PANAGORA ASSET MANAGEMENT INC | 57,016 | 0 | 0 | 0 | For |
| Wellington | 55,327 | 0 | 0 | 0 | For |
| Dimensional | 44,568 | 0 | 0 | 0 | For |
Institutional-manager reports, all 130 managers: 17,261,477 for, 348,365 against. Showing the 25 largest; see all in the interactive database.
Combines 3 wordings of this item as funds reported it.
99.8% Approved · of votes cast
Description as filed by funds: To ratify the appointment of PricewaterhouseCoopers LLP as Enanta's independent registered public accounting firm for the 2026 fiscal year.
Enanta Pharmaceuticals, Inc.’s own tally for this item (“4. To Ratify the Appointment of PricewaterhouseCoopers LLP as Enanta's Independent Registered Public Accounting Firm for the 2026 Fiscal Year”): 26,825,173 for, 26,904 against — passed, per its Form 8-K filed March 12, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The stockholders ratified the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending September 30, 2026.”
Support: 99.8% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 49 asset managers below reported 5,870,874 for, 1,015 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,102,722 | 0 | 0 | 0 | For |
| BlackRock | 1,930,161 | 0 | 0 | 0 | For |
| Fidelity | 563,274 | 0 | 0 | 0 | For |
| Charles Schwab | 270,405 | 0 | 0 | 0 | For |
| Invesco | 223,352 | 0 | 0 | 0 | For |
| Dimensional | 88,219 | 0 | 0 | 0 | For |
| Goldman Sachs | 86,245 | 0 | 0 | 0 | For |
| TIAA | 84,434 | 0 | 0 | 0 | For |
| Equitable | 66,564 | 0 | 0 | 0 | For |
| JPMorgan | 62,555 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 46,159 | 0 | 0 | 0 | For |
| TARGET PORTFOLIO TRUST | 33,700 | 0 | 0 | 0 | For |
| Thrivent | 27,269 | 0 | 0 | 0 | For |
| Brighthouse | 26,289 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 25,428 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 25,000 | 0 | 0 | 0 | For |
| Northern Trust | 22,122 | 0 | 0 | 0 | For |
| Lincoln Financial | 20,378 | 0 | 0 | 0 | For |
| Nationwide | 17,210 | 0 | 0 | 0 | For |
| Franklin Templeton | 16,948 | 0 | 0 | 0 | For |
| Putnam | 14,847 | 0 | 0 | 0 | For |
| Global X | 12,668 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 12,096 | 0 | 0 | 0 | For |
| Pacific Life | 10,277 | 0 | 0 | 0 | For |
| SEI | 8,815 | 1,015 | 0 | 0 | Mixed |
Showing the 25 largest of 49 asset managers. See all 49 in the interactive database.
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 29,019,344 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 7.25% |
| 2 | BlackRock | 6.65% |
| 3 | Fidelity | 1.94% |
| 4 | Charles Schwab | 0.93% |
| 5 | Invesco | 0.77% |
| 6 | Dimensional | 0.30% |
| 7 | Goldman Sachs | 0.30% |
| 8 | TIAA | 0.29% |
| 9 | Equitable | 0.23% |
| 10 | JPMorgan | 0.22% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Janus Henderson | 23.66% |
| 2 | FARALLON CAPITAL MANAGEMENT, L.L.C. | 9.55% |
| 3 | Deep Track Capital, LP | 6.74% |
| 4 | BlackRock | 2.99% |
| 5 | ACADIAN ASSET MANAGEMENT LLC | 2.24% |
| 6 | GEODE CAPITAL MANAGEMENT, LLC | 2.23% |
| 7 | State Street | 1.69% |
| 8 | Hillsdale Investment Management Inc. | 1.42% |
| 9 | Invesco | 0.95% |
| 10 | Charles Schwab | 0.93% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| Janus Henderson Group plc and certain affiliates | 12.04% | DEF14A |
| BlackRock | 10.70% | 13F |
| Dapice Joshua J. | 9.71% | 13G |
| Vanguard Group | 7.93% | 13F |
| Farallon Capital Management, LLC | 7.31% | DEF14A |
| Krensavage Asset Management, LLC | 7.29% | DEF14A |
| Jay R. Luly, Ph.D. | 6.03% | DEF14A |
| Deep Track Capital, LP and certain affiliates | 5.12% | DEF14A |
| Millennium Management | 3.04% | 13F |
| Integrated Core Strategies (US) LLC | 2.29% | 13G |
Percentages above are of 29,019,344 shares outstanding, as reported by Enanta Pharmaceuticals, Inc. on its Form 10-Q dated February 5, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Enanta Pharmaceuticals, Inc.’s 10-Q dated February 5, 2026. This page is a static snapshot rebuilt weekly on October 18, 2026; a live search always shows the current data.
At Enanta Pharmaceuticals, Inc.'s shareholder meeting held March 11, 2026, in the 2025-2026 proxy season, 161 asset managers reported how they voted on 5 ballot items in their SEC Form N-PX filings, covering 945 separate fund positions. On the most widely held item on that ballot — TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION PAID TO OUR NAMED EXECUTIVE OFFICERS, AS… — Enanta Pharmaceuticals, Inc.'s filing reports the proposal as approved, with 97% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Enanta Pharmaceuticals, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on March 12, 2026.
Enanta Pharmaceuticals, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).
Download data (CSV): ballot items · votes by manager · column guide.